Regulatory and evidence-based considerations for abuse-deterrent opioids.
作者信息
Loeser Kathryn C, Rodriguez Ryan
机构信息
Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL.
College of Pharmacy, University of Illinois at Chicago, Chicago, IL.
出版信息
Am J Health Syst Pharm. 2019 Jan 16;76(2):114-118. doi: 10.1093/ajhp/zxy013.
PMID:30689701
Abstract
摘要
相似文献
1
Regulatory and evidence-based considerations for abuse-deterrent opioids.滥用威慑型阿片类药物的监管及循证考量
Am J Health Syst Pharm. 2019 Jan 16;76(2):114-118. doi: 10.1093/ajhp/zxy013.
2
Abuse-deterrent formulations of opioids: Many questions still to answer.阿片类药物的抗滥用制剂：仍有许多问题有待解答。
J Opioid Manag. 2017 Nov/Dec;13(6):353-356. doi: 10.5055/jom.2017.0402.
3
Opioids with abuse-deterrent properties: A regulatory and technological overview.具有滥用威慑特性的阿片类药物：监管与技术概述。
J Opioid Manag. 2017 Nov/Dec;13(6):397-413. doi: 10.5055/jom.2017.0417.
4
Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?滥用防范阿片类药物制剂：预防阿片灾难的关键因素？
Clin Drug Investig. 2018 Jul;38(7):573-577. doi: 10.1007/s40261-018-0651-3.
5
Abuse-deterrent opioids: an update on current approaches and considerations.阿片类药物滥用威慑：当前方法与考量的最新进展
Curr Med Res Opin. 2018 Apr;34(4):711-723. doi: 10.1080/03007995.2017.1419171. Epub 2018 Jan 10.
6
Safety and performance of current abuse-deterrent formulations.现行防滥用配方的安全性和性能。
Expert Opin Drug Metab Toxicol. 2018 Dec;14(12):1255-1271. doi: 10.1080/17425255.2018.1546289. Epub 2018 Dec 2.
7
Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.阿片类药物滥用预防制剂对美国慢性疼痛患者的影响：成本效益模型。
Value Health. 2019 Apr;22(4):416-422. doi: 10.1016/j.jval.2018.12.005. Epub 2019 Mar 21.
8
Letter to the Editor: Opioid Overdose Protection: An Inevitable Need to Address an Alarming Epidemic.致编辑的信：阿片类药物过量防护：应对一场惊人的流行病的必然需求。
J Opioid Manag. 2017 Nov/Dec;13(6):363-364. doi: 10.5055/jom.2017.0414.
9
Abuse-deterrent formulations approval reform: Will clinical correctness or real-world results be used to address the nation's opioid crisis: "Noninterference" as a new approval standard.滥用威慑制剂批准改革：将以临床正确性还是现实世界结果来应对国家阿片类药物危机：“不干扰”作为一项新的批准标准。
J Opioid Manag. 2017 Nov/Dec;13(6):357-362. doi: 10.5055/jom.2017.0413.
10
Interpreting labels of abuse-deterrent opioid analgesics.解读阿片类镇痛药物滥用威慑标签
J Opioid Manag. 2017 Nov/Dec;13(6):415-423. doi: 10.5055/jom.2017.0418.
Zotero 插件